141 related articles for article (PubMed ID: 32118719)
21. [A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis].
Hu JY; Zhou HB; Liu WD; Zhang J; Hu HP; Liu J
Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):511-515. PubMed ID: 31357776
[No Abstract] [Full Text] [Related]
22. Update on Ancillary Testing in the Evaluation of High-Grade Liver Tumors.
Koehne de Gonzalez A; Lagana SM
Surg Pathol Clin; 2018 Jun; 11(2):367-375. PubMed ID: 29751880
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Brychtova V; Zampachova V; Hrstka R; Fabian P; Novak J; Hermanova M; Vojtesek B
Exp Mol Pathol; 2014 Jun; 96(3):375-81. PubMed ID: 24747240
[TBL] [Abstract][Full Text] [Related]
24. Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis.
Jiang K; Centeno BA
Cancer Control; 2018; 25(1):1073274817744658. PubMed ID: 29353494
[TBL] [Abstract][Full Text] [Related]
25. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
[TBL] [Abstract][Full Text] [Related]
26. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
27. Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma.
Sang W; Zhang W; Cui W; Li X; Abulajiang G; Li Q
Tumour Biol; 2015 May; 36(5):3881-6. PubMed ID: 25577247
[TBL] [Abstract][Full Text] [Related]
28. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
29. Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Burkhart RA; Pawlik TM
Cancer Control; 2017; 24(3):1073274817729235. PubMed ID: 28975828
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer.
Liu S; Wang M; Zheng C; Zhong Q; Shi Y; Han X
Clin Biochem; 2020 May; 79():54-60. PubMed ID: 32087138
[TBL] [Abstract][Full Text] [Related]
31. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
32. SMARCB1/INI1 Is Diagnostically Useful in Distinguishing α-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Kondo T
Anticancer Res; 2018 Dec; 38(12):6865-6868. PubMed ID: 30504402
[TBL] [Abstract][Full Text] [Related]
33. The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.
Ferrone CR; Ting DT; Shahid M; Konstantinidis IT; Sabbatino F; Goyal L; Rice-Stitt T; Mubeen A; Arora K; Bardeesey N; Miura J; Gamblin TC; Zhu AX; Borger D; Lillemoe KD; Rivera MN; Deshpande V
Ann Surg Oncol; 2016 Jan; 23(1):290-6. PubMed ID: 25519926
[TBL] [Abstract][Full Text] [Related]
34. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.
Ono Y; Hiratsuka Y; Murata M; Takasawa A; Fukuda R; Nojima M; Tanaka S; Osanai M; Hirata K; Sawada N
Virchows Arch; 2016 Oct; 469(4):417-26. PubMed ID: 27444172
[TBL] [Abstract][Full Text] [Related]
35. Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma.
Yamamoto M; Ariizumi S; Otsubo T; Katsuragawa H; Katagiri S; Nakano M; Takasaki K
J Surg Oncol; 2004 Aug; 87(2):80-3; discussion 83-4. PubMed ID: 15282700
[TBL] [Abstract][Full Text] [Related]
36. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
37. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
38. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
39. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.
McKnight R; Nassar A; Cohen C; Siddiqui MT
Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472
[TBL] [Abstract][Full Text] [Related]
40. Synchronous occurrence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in both lobes of the liver.
Topaloğlu S; Sağlam K; Çalık A; Cobanoğlu Ü; Öztürk MH
Turk J Gastroenterol; 2014 Apr; 25(2):209-11. PubMed ID: 25003684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
